Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.40%
Dec 31, 2025 10.64%
Sep 30, 2025 56.32%
Jun 30, 2025 20.75%
Mar 31, 2025 -1.61%
Dec 31, 2024 25.34%
Sep 30, 2024 24.27%
Jun 30, 2024 -1.48%
Mar 31, 2024 -33.76%
Dec 31, 2023 38.19%
Sep 30, 2023 2.15%
Jun 30, 2023 -9.97%
Mar 31, 2023 -7.83%
Dec 31, 2022 19.51%
Sep 30, 2022 -4.96%
Jun 30, 2022 -15.63%
Mar 31, 2022 -64.81%
Dec 31, 2021 -32.19%
Sep 30, 2021 -1.81%
Jun 30, 2021 -12.34%